BRILLIANT I

BRILLIANT I

A trial designed to demonstrate the safety of the Batimastat BiodivYsio stent, in a 150-patient cohort that underwent angiography at 6 months. Review of the data from BRILLIANT I did not show the benefit that was evident in the pre-clinical studies, which led to suspension of patient recruitment for BRILLIANT II.